Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 55
Filtrar
1.
J Hosp Infect ; 142: 88-95, 2023 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-37802238

RESUMEN

Extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli bacteraemia can induce unfavourable clinical outcomes due to delay in appropriate antimicrobial treatment and limited therapeutic options. Therefore, elucidating the predictors of ESBL-producing E. coli-induced bacteraemia is crucial to improve clinical outcomes. However, a literature search did not reveal any studies that incorporate a meta-analysis of the predictors of ESBL-producing E. coli-induced bacteraemia. As such, this review was undertaken to assess current evidence on the predictors of ESBL-producing E. coli-induced bacteraemia. PubMed, Web of Science and Cochrane Library databases were searched for all relevant publications from January 2000 to September 2021. This systematic review evaluated 10 observational studies, comprising a total of 2325 patients with E. coli-induced bacteraemia and 850 (36.6%) ESBL-producing strains. In the meta-analysis, previous antibiotic therapy [pooled risk ratio (RR) 2.72; P<0.001], especially with cephalosporins (pooled RR 4.66; P<0.001) and quinolones (pooled RR 5.47; P<0.001), and urinary catheter use (pooled RR 3.79; P<0.001) were predictive of ESBL-producing E. coli-induced bacteraemia. Antibiotic therapy for patients with the above-mentioned risk factors should be selected considering the possibility of ESBL-producing E. coli-induced bacteraemia compared with non-ESBL-producing E. coli-induced bacteraemia. It is important to elucidate whether appropriate modulation of the identified risk factors can potentially mitigate the risk of ESBL-producing E. coli-induced bacteraemia compared with non-ESBL-producing E. coli-induced bacteraemia.


Asunto(s)
Bacteriemia , Infecciones por Escherichia coli , Humanos , Escherichia coli , Infecciones por Escherichia coli/epidemiología , Infecciones por Escherichia coli/tratamiento farmacológico , beta-Lactamasas , Factores de Riesgo , Antibacterianos/uso terapéutico , Bacteriemia/epidemiología , Bacteriemia/tratamiento farmacológico
2.
J Hosp Infect ; 134: 153-160, 2023 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-36813165

RESUMEN

BACKGROUND: Hypervirulent Klebsiella pneumoniae (hvKp) infections confer notable morbidity and mortality. Differential diagnosis to determine whether the infections are caused by either the hvKp or classical K. pneumoniae (cKp) strain is particularly important for undertaking optimal clinical care and infection control efforts. AIM: To identify and assess the potential predictors of hvKp infections. METHODS: PubMed, Web of Science, and Cochrane Library databases were searched for all relevant publications from January 2000 to March 2022. The search terms included a combination of the following terms: (i) Klebsiella pneumoniae or K. pneumoniae and (ii) hypervirulent or hypervirulence. A meta-analysis of factors for which risk ratio was reported in three or more studies was conducted, and at least one statistically significant association was identified. FINDINGS: In this systematic review of 11 observational studies, a total of 1392 patients with K. pneumoniae infection and 596 (42.8%) with hvKp strains were evaluated. In the meta-analysis, diabetes mellitus and liver abscess (pooled risk ratio: 2.61 (95% confidence interval: 1.79-3.80) and 9.04 (2.58-31.72), respectively; all P < 0.001) were predictors of hvKp infections. CONCLUSION: For patients with a history of the abovementioned predictors, prudent management, including the search for multiple sites of infection and/or metastatic spread and the enforcement of an early and appropriate source control procedure, should be initiated in consideration of the potential presence of hvKp. We believe that this research highlights the urgent need for increasing clinical awareness of the management of hvKp infections.


Asunto(s)
Infecciones por Klebsiella , Factores de Virulencia , Humanos , Virulencia , Klebsiella pneumoniae , Infecciones por Klebsiella/diagnóstico , Antibacterianos/uso terapéutico
3.
QJM ; 115(8): 539, 2022 08 13.
Artículo en Inglés | MEDLINE | ID: mdl-35703982
4.
J Hosp Infect ; 111: 169-175, 2021 May.
Artículo en Inglés | MEDLINE | ID: mdl-33516796

RESUMEN

BACKGROUND: Stenotrophomonas maltophilia is a pathogen commonly associated with respiratory infection. However, the characteristics of pneumonia caused by S. maltophilia remain unknown. AIM: To evaluate the characteristics of and risk factors for S. maltophilia pneumonia. METHODS: A retrospective evaluation was undertaken of 2002 patients with sputum cultures positive for S. maltophilia between January 2010 and December 2019. Cases were excluded based on clinical information and laboratory results. Included cases were divided into two groups: the S. maltophilia pneumonia group (patients with pneumonia caused by S. maltophilia) and the non-S. maltophilia pneumonia group (patients with pneumonia caused by pathogens other than S. maltophilia). Patient characteristics, clinical data and Sequential Organ Failure Assessment (SOFA) scores were compared between the groups. FINDINGS: Eight and 91 patients were assigned to the S. maltophilia pneumonia and non-S. maltophilia pneumonia groups, respectively. The median age was significantly lower in the S. maltophilia pneumonia group than in the non-S. maltophilia pneumonia group (63.4 vs 73.1 years; P<0.01), and the SOFA score was significantly higher in the S. maltophilia pneumonia group (7.5 vs 3.0; P<0.01). Underlying malignancy and pre-administration of antipseudomonal ß-lactams and steroids were confirmed in seven of the eight cases in the S. maltophilia pneumonia group, suggesting an association with immunosuppression. CONCLUSIONS: Pneumonia due to S. maltophilia is a rare occurrence. Treatment for this pathogen should be considered in cases of pneumonia with: (1) predominance of S. maltophilia in sputum cultures; (2) pre-administration of broad-spectrum antibiotics; (3) immunodeficiency; and (4) a high SOFA score.


Asunto(s)
Infecciones por Bacterias Gramnegativas , Neumonía Bacteriana , Stenotrophomonas maltophilia , Antibacterianos/uso terapéutico , Infecciones por Bacterias Gramnegativas/tratamiento farmacológico , Humanos , Neumonía Bacteriana/tratamiento farmacológico , Estudios Retrospectivos , Stenotrophomonas maltophilia/aislamiento & purificación
6.
Transpl Infect Dis ; 17(5): 647-54, 2015 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-26134140

RESUMEN

BACKGROUND: Fluoroquinolones are widely used for antibacterial prophylaxis during neutropenia following hematopoietic stem cell transplantation (HSCT). Nevertheless, data are inadequate as to whether fluoroquinolones decrease mortality rate compared with other antibiotics. METHODS: We retrospectively compared the efficacy of antibacterial prophylaxis using non-absorbable polymyxin B (PB) (n = 106) or systemic levofloxacin (LVFX) (n = 140) after allogeneic SCT at our institute between 2004 and 2013. RESULTS: No significant difference was observed between the 2 groups in the cumulative incidences of failure of prophylaxis (P = 0.21), clinically documented infections (P = 0.70), or non-relapse mortality within the first 100 days after transplantation (P = 0.42). With bacteremia, the rate of resistance to LVFX was 82% in the PB group and 100% in the LVFX group (P = 0.41). Also, no significant difference was found in overall survival between the 2 groups (P = 0.78). CONCLUSION: Our results indicate no difference in the effectiveness of antibacterial prophylaxis between systemic antibiotic LVFX and non-absorbable antibiotic PB.


Asunto(s)
Antibacterianos/uso terapéutico , Profilaxis Antibiótica/métodos , Infecciones Bacterianas/prevención & control , Trasplante de Células Madre Hematopoyéticas , Levofloxacino/uso terapéutico , Infecciones Oportunistas/prevención & control , Polimixina B/uso terapéutico , Administración Tópica , Adolescente , Adulto , Anciano , Infecciones Bacterianas/inmunología , Femenino , Estudios de Seguimiento , Humanos , Huésped Inmunocomprometido , Masculino , Persona de Mediana Edad , Infecciones Oportunistas/inmunología , Estudios Retrospectivos , Trasplante Homólogo , Adulto Joven
7.
Lett Appl Microbiol ; 53(1): 35-43, 2011 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-21554343

RESUMEN

AIMS: Oral administration of probiotics has been known to improve inflammatory responses against infectious diseases. Here, we describe the inhibitory effect of oral intake of heat-killed Lactobacillus pentosus strain b240 (b240) on pneumococcal pneumonia in a murine experimental model. METHOD AND RESULTS: The mice treated with oral b240 for 21 days before Streptococcus pneumoniae infection exhibited prolonged survival time and less body weight loss, compared with saline-treated control mice. Mild pneumonia with significantly reduced secretion of inflammatory cytokines/chemokines according to related mitogen-activated protein kinase signalling molecules (phosphorylated c-Jun N-terminal kinase) was found in b240-treated mice, whereas severe pneumonia with hypercytokinemia was evident in control mice. Prominent reduction in the number of pneumococci and elevated expression of Toll-like receptor 2 and 4 in the lung tissues was concomitantly noted in b240-treated mice. CONCLUSIONS: These findings indicate that b240 has inhibitory effects on pneumococcal pneumonia induced by Strep. pneumoniae infection and improves inflammatory tissue responses, resulting in reduced damages to the respiratory tissues. SIGNIFICANCE AND IMPACT OF THE STUDY: These results demonstrate that oral administration of b240 might protect host animals from Strep. pneumoniae infection by augmentation of innate immune response.


Asunto(s)
Lactobacillus , Neumonía Neumocócica/inmunología , Probióticos/administración & dosificación , Streptococcus pneumoniae , Animales , Citocinas/inmunología , Citocinas/metabolismo , Lactobacillus/clasificación , Pulmón/inmunología , Pulmón/microbiología , Sistema de Señalización de MAP Quinasas , Masculino , Ratones , Ratones Endogámicos BALB C , Neumonía Neumocócica/microbiología , Organismos Libres de Patógenos Específicos , Receptores Toll-Like/inmunología
9.
J Int Med Res ; 36(2): 322-8, 2008.
Artículo en Inglés | MEDLINE | ID: mdl-18380943

RESUMEN

Gabexate mesilate is a synthetic protease inhibitor that is effective for acute pancreatitis. The effect of gabexate mesilate in influenza pneumonia in mice was investigated by examining the changes in pulmonary inflammatory cytokines and chemokines. Pathological changes in the lungs of treated mice were extremely mild, compared with changes in infected, untreated mice. Intrapulmonary levels of interleukin-6 and macrophage inflammatory protein-2 decreased in treated mice compared with untreated mice, despite similar viral titres in the lungs. Survival terms for treated and untreated groups were similar. These data indicate that gabexate mesilate has beneficial effects on influenza pneumonia, which may be due to the modulation of inflammatory cytokine/chemokine responses.


Asunto(s)
Antivirales/administración & dosificación , Citocinas/antagonistas & inhibidores , Gabexato/administración & dosificación , Subtipo H1N1 del Virus de la Influenza A/efectos de los fármacos , Infecciones por Orthomyxoviridae/tratamiento farmacológico , Neumonía Viral/tratamiento farmacológico , Animales , Línea Celular , Modelos Animales de Enfermedad , Perros , Subtipo H1N1 del Virus de la Influenza A/inmunología , Masculino , Ratones , Ratones Endogámicos CBA , Infecciones por Orthomyxoviridae/inmunología , Infecciones por Orthomyxoviridae/patología , Neumonía Viral/inmunología , Neumonía Viral/patología , Distribución Aleatoria
10.
Clin Exp Immunol ; 152(2): 364-71, 2008 May.
Artículo en Inglés | MEDLINE | ID: mdl-18341613

RESUMEN

Severe pneumonia is found in simultaneous influenza pneumonia and bacterial infection, and suggests a relationship with immunological mechanisms. Here, we performed two-dimensional gel electrophoresis to detect immunological molecules related to the fulminant pneumonia caused by influenza virus and Streptococcus pneumoniae co-infection in mice. We found two spots that were expressed strongly in co-infected mouse lungs, compared with S. pneumoniae or influenza virus singly infected mouse lungs. The spots were analysed by mass spectrometry, and identified as alpha-1 anti-trypsin (A1AT), known as an anti-protease for neutrophil-derived proteolytic enzymes, and creatine kinase, which reflects a greater degree of lung damage and cell death. A1AT expression was increased significantly, and proteolytic enzymes from neutrophils, such as neutrophil elastase, myeloperoxidase and lysozyme, were also secreted abundantly in influenza virus and S. pneumoniae co-infected lungs compared with S. pneumoniae or influenza virus singly infected lungs. These data suggest that A1AT may play a central role as a molecule with broad anti-inflammatory properties, and regulation of the neutrophil-mediated severe lung inflammation is important in the pathogenesis of co-infection with influenza virus and bacteria.


Asunto(s)
Virus de la Influenza A , Infecciones por Orthomyxoviridae/complicaciones , Neumonía Neumocócica/complicaciones , Neumonía Viral/complicaciones , Animales , Líquido del Lavado Bronquioalveolar/química , Quimiocina CXCL2/metabolismo , Creatina Quinasa/metabolismo , Susceptibilidad a Enfermedades , Electroforesis en Gel Bidimensional/métodos , Elastasa de Leucocito/metabolismo , Pulmón/metabolismo , Masculino , Ratones , Ratones Endogámicos CBA , Muramidasa/metabolismo , Infecciones por Orthomyxoviridae/inmunología , Peroxidasa/metabolismo , Neumonía Neumocócica/inmunología , Neumonía Viral/inmunología , alfa 1-Antitripsina/metabolismo
11.
J Antibiot (Tokyo) ; 54(10): 783-8, 2001 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-11776432

RESUMEN

We have developed a novel p21WAF1 promoter activator screening system based on rapid and facile luciferase activity assay of a model cell system (H1299/tsp53-luc cells), a stable luciferase expression cell line established by transfecting H1299/tsp53 cells with a reporter gene construct pWWP-Luc-BSD. This plasmid was constructed by subcloning the 2.4 kb p21WAF1 promoter and a 2.6 kb of luciferase cDNA fragment activated by the p21WAF1 promoter into a pMAM2-BSD expression vector containing the blasticidin S deaminase gene (BSD). A BSD-resistant clone H1299/tsp53-luc#4, showing the highest response to p53 activation (by temperature shift from 37 degrees C to 32 degrees C) by luciferase production, was used for screening microbial culture broths. Among approximately 1200 screened samples, trichostatin A related compounds and a new compound, lucilactaene, were isolated. This provides an effective and facile screening system for p21WAF1 promoter activators which should be of considerable value in the rapid identification of new anticancer agents.


Asunto(s)
Antibióticos Antineoplásicos/biosíntesis , Bacterias/genética , Bacterias/metabolismo , Ciclinas/genética , Inhibidores Enzimáticos/farmacología , Regulación de la Expresión Génica/efectos de los fármacos , Regiones Promotoras Genéticas/efectos de los fármacos , Antibióticos Antineoplásicos/farmacología , Ciclo Celular/efectos de los fármacos , Medios de Cultivo , Inhibidor p21 de las Quinasas Dependientes de la Ciclina , ADN Bacteriano/biosíntesis , ADN Bacteriano/genética , ADN Complementario/biosíntesis , ADN Complementario/genética , Evaluación Preclínica de Medicamentos/métodos , Genes p53/genética , Luciferasas/biosíntesis , Luciferasas/metabolismo , Plásmidos/genética , Transfección , Células Tumorales Cultivadas
13.
Chemotherapy ; 47(6): 421-9, 2001 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-11786657

RESUMEN

BACKGROUND AND METHODS: We compared the bacteriological, pharmacological and histopathological effects of parenterally administered ciprofloxacin (CPFX) to those of imipenem/cilastatin (IMP/CS) and cefozopran (CZOP) in a murine model of mucoid Pseudomonas aeruginosa pneumonia mimicking ventilator-associated pneumonia. RESULTS: The minimum inhibitory concentrations (MICs) of CPFX, IMP and CZOP were 1.0, 1.0 and 4.0 mg/l, respectively. Treatment with CPFX resulted in a significant decrease in the number of viable bacteria [control, IMP/CS, CZOP and CPFX (mean +/- SEM): 5.02 +/- 0.20, 4.96 +/- 0.38, 5.44 +/- 0.13 and 3.27 +/- 0.02 log(10) colony-forming units lung, respectively]. Histopathological examination revealed that inflammatory changes in the CPFX-treated group were less marked than in other groups. Of the drugs analyzed, the pharmacokinetic parameters of area under the time-concentration curve (AUC)/MIC, AUC exceeding MIC and the time that lung concentrations of drug remained above the MIC were highest for CPFX. CONCLUSION: Our results suggest that parenterally administered ciprofloxacin is effective in ventilator-associated P. aeruginosa pneumonia.


Asunto(s)
Antiinfecciosos/farmacología , Cefalosporinas/farmacología , Cilastatina/farmacología , Ciprofloxacina/farmacología , Imipenem/farmacología , Neumonía Bacteriana/tratamiento farmacológico , Inhibidores de Proteasas/farmacología , Infecciones por Pseudomonas/tratamiento farmacológico , Pseudomonas aeruginosa/patogenicidad , Respiración Artificial/efectos adversos , Tienamicinas/farmacología , Animales , Antiinfecciosos/administración & dosificación , Antiinfecciosos/farmacocinética , Área Bajo la Curva , Cefalosporinas/administración & dosificación , Cefalosporinas/farmacocinética , Cilastatina/administración & dosificación , Cilastatina/farmacocinética , Ciprofloxacina/administración & dosificación , Ciprofloxacina/farmacocinética , Modelos Animales de Enfermedad , Imipenem/administración & dosificación , Imipenem/farmacocinética , Infusiones Parenterales , Masculino , Ratones , Neumonía Bacteriana/veterinaria , Inhibidores de Proteasas/administración & dosificación , Inhibidores de Proteasas/farmacocinética , Infecciones por Pseudomonas/veterinaria , Tienamicinas/administración & dosificación , Tienamicinas/farmacocinética , Cefozoprán
14.
Antimicrob Agents Chemother ; 44(11): 2985-90, 2000 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-11036010

RESUMEN

High-level azole resistance in the Darlington strain of Candida albicans was investigated by gene replacement in C. albicans and expression in Saccharomyces cerevisiae. We sequenced the ERG11 gene, which encodes the sterol C(14)alpha-demethylase, from our copy of the Darlington strain. Both alleles contained the histidine for tyrosine substitution at position 132 (Y132H) reported in Darlington by others, but we also found a threonine-for-isoleucine substitution (I471T) not previously reported in the C. albicans ERG11. The encoded I471T change in amino acids conferred azole resistance when overexpressed alone and increased azole resistance when added to the Y132H amino acid sequence in an S. cerevisiae expression system. Replacement of one copy of ERG11 in an azole-susceptible strain of C. albicans with a single copy of the Darlington ERG11 resulted in expression of the integrated copy and a modest increase in azole resistance. The profound azole resistance of the Darlington strain is the result of multiple mutations.


Asunto(s)
Antifúngicos/farmacología , Candida albicans/genética , Cromosomas Fúngicos/genética , Sistema Enzimático del Citocromo P-450/genética , Fluconazol/farmacología , Oxidorreductasas/genética , Sustitución de Aminoácidos , Candida albicans/efectos de los fármacos , Farmacorresistencia Microbiana/genética , Pruebas de Sensibilidad Microbiana , Mutagénesis Sitio-Dirigida , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Saccharomyces cerevisiae/genética , Esterol 14-Desmetilasa , Transfección
15.
J Biol Chem ; 275(12): 8766-71, 2000 Mar 24.
Artículo en Inglés | MEDLINE | ID: mdl-10722720

RESUMEN

We found that antitumor drugs such as cytotrienin A, camptothecin, taxol, and 5-fluorouracil induced the activation of a 36-kDa protein kinase (p36 myelin basic protein (MBP) kinase) during apoptosis in human promyelocytic leukemia HL-60 cells. This p36 MBP kinase, which phosphorylates MBP in an in-gel kinase assay, results from the caspase-3-mediated proteolytic cleavage of MST/Krs protein, a mammalian Ste20-like serine/threonine kinase. Herein the correlation between cytotrienin A-induced apoptosis and the activation of MST/Krs proteins was examined in human tumor cell lines, including leukemia-, lung-, epidermoid-, cervix-, stomach-, and brain-derived cell lines. In cytotrienin A-sensitive cell lines, we observed a strong activation of p36 MBP kinase by cleavage of the C-terminal regulatory domain of full-length MST/Krs proteins by caspase-3. When the kinase-inactive mutant form of MST/Krs protein was overexpressed in cytotrienin A-sensitive HL-60 cells, the cytotrienin A-induced apoptosis was partially inhibited. Because cytotrienin A also activated c-Jun N-terminal kinase, we examined the effect of the expression of dominant negative c-Jun on cytotrienin A-induced apoptosis. The expression of dominant negative c-Jun also partially inhibited cytotrienin A-induced apoptosis. Furthermore, coexpression of kinase-inactive MST/Krs protein and dominant negative c-Jun completely suppressed cytotrienin A-induced apoptosis. These findings suggest that the proteolytic activation of MST/Krs and c-Jun N-terminal kinase activation are involved in cytotrienin A-induced apoptosis in human tumor cell lines.


Asunto(s)
Antibióticos Antineoplásicos/farmacología , Apoptosis , Quinasas Quinasa Quinasa PAM , Proteínas Quinasas Activadas por Mitógenos/metabolismo , Proteínas Serina-Treonina Quinasas/metabolismo , Rifamicinas/farmacología , Proteínas Quinasas Dependientes de Calcio-Calmodulina/metabolismo , Caspasa 3 , Caspasas/metabolismo , Glucógeno Sintasa Quinasa 3 , Humanos , Proteínas Quinasas JNK Activadas por Mitógenos , Modelos Biológicos , Proteínas Proto-Oncogénicas/metabolismo , Proteínas Proto-Oncogénicas c-bcl-2/metabolismo , Proteínas Proto-Oncogénicas c-jun/metabolismo , Transducción de Señal , Células Tumorales Cultivadas/efectos de los fármacos , Proteína X Asociada a bcl-2
16.
IEEE Trans Neural Netw ; 11(6): 1323-31, 2000.
Artículo en Inglés | MEDLINE | ID: mdl-18249857

RESUMEN

This paper presents an algorithm which realizes fast search for the solutions of combinatorial optimization problems with parallel digital computers.With the standard weight matrices designed for combinatorial optimization, many iterations are required before convergence to a quasioptimal solution even when many digital processors can be used in parallel. By removing the components of the eingenvectors with eminent negative eigenvalues of the weight matrix, the proposed algorithm avoids oscillation and realizes energy reduction under synchronous discrete dynamics, which enables parallel digital computers to obtain quasi-optimal solutions with much less time than the conventional algorithm.

17.
J Antimicrob Chemother ; 44(6): 827-9, 1999 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-10590286

RESUMEN

The in-vitro and in-vivo activities of SCH56592, a triazole antifungal agent, against Cryptococcus neoformans were studied. MIC(90)s for 16 strains of C. neoformans measured by microdilution method (NCCLS M27-A) were 1 mg/L of SCH56592, 16 mg/L of fluconazole, 32 mg/L of flucytosine, and 0.5 mg/L of amphotericin B. In a murine model of pulmonary cryptococcosis, 10 mg/kg of SCH56592 was more effective than fluconazole. The fungal burden of the lung of animals treated with SCH56592 was significantly reduced (7.40 +/- 0.21 log(10) cfu/g), as compared with fluconazole (7.77 +/- 0.07 log(10) cfu/g) and control (7.79 +/- 0.1 log(10) cfu/g) (P < 0.01). For C. neoformans-infected mice following 7 days treatment with 10 mg/kg of SCH56592 there was a higher concentration in lung (3.36 +/- 0.62 ng/ml) than in plasma (2.16 +/- 0.86 ng/mL), and this was maintained for 12 h after administration.


Asunto(s)
Antifúngicos/uso terapéutico , Criptococosis/tratamiento farmacológico , Cryptococcus neoformans/efectos de los fármacos , Triazoles/uso terapéutico , Animales , Antifúngicos/farmacocinética , Antifúngicos/farmacología , Encéfalo/microbiología , Recuento de Colonia Microbiana , Criptococosis/microbiología , Cryptococcus neoformans/aislamiento & purificación , Humanos , Pulmón/microbiología , Enfermedades Pulmonares Fúngicas/tratamiento farmacológico , Enfermedades Pulmonares Fúngicas/microbiología , Ratones , Pruebas de Sensibilidad Microbiana , Triazoles/farmacocinética , Triazoles/farmacología
18.
Oncogene ; 18(37): 5211-20, 1999 Sep 16.
Artículo en Inglés | MEDLINE | ID: mdl-10498871

RESUMEN

Fas is a well characterized apoptosis-inducing factor. One of our synthetic compounds, MT-21, induced apoptosis in human leukemia HL-60 cells similar to Fas. MT-21 activated caspase-3, an important cysteine aspartic protease for apoptosis induction. MT-21 also activated c-Jun-NH2-terminal kinase (JNK), a member of mitogen activated protein kinase (MAPK) superfamily that is involved in the regulation of cell growth, differentiation and cell death. Moreover, MT-21 treatment resulted in the activation of a 36 kDa kinase which uses myelin basic protein (MBP) as a substrate. However, MAPK and p38 were not activated by treatment with MT-21. The 36 kDa MBP kinase was shown to be a proteolytic product derived from the Krs protein with a molecular weight of 60 kDa. The Krs protein is a Ser/Thr protein kinase whose activity is enhanced by digestion of its C-terminal regulatory domain by caspase-3. When a kinase-inactive mutant form of Krs protein was overexpressed in HL-60 cells, JNK activation and apoptosis induction by MT-21 were suppressed. Furthermore, overexpression of dominant negative c-Jun also suppressed apoptosis induction by MT-21. These findings indicate that MT-21 induces apoptosis by the activation of JNK via the Krs protein, which is activated by caspase cleavage.


Asunto(s)
Apoptosis/efectos de los fármacos , Proteínas Quinasas Activadas por Mitógenos , Proteínas Serina-Treonina Quinasas/fisiología , Pirroles/farmacología , Transducción de Señal/efectos de los fármacos , Sustitución de Aminoácidos , Apoptosis/fisiología , Proteínas Quinasas Dependientes de Calcio-Calmodulina/metabolismo , Caspasa 3 , Caspasas/metabolismo , Fragmentación del ADN , ADN de Neoplasias/metabolismo , Activación Enzimática/efectos de los fármacos , Proteína Ligando Fas , Genes jun , Células HL-60/efectos de los fármacos , Células HL-60/enzimología , Humanos , Péptidos y Proteínas de Señalización Intracelular , Proteínas Quinasas JNK Activadas por Mitógenos , Glicoproteínas de Membrana/farmacología , Mutagénesis Sitio-Dirigida , Proteína Básica de Mielina/metabolismo , Proteínas de Neoplasias/metabolismo , Fragmentos de Péptidos/metabolismo , Poli(ADP-Ribosa) Polimerasas/metabolismo , Proteínas Serina-Treonina Quinasas/genética , Especies Reactivas de Oxígeno , Serina-Treonina Quinasa 3 , Células U937/efectos de los fármacos , Células U937/enzimología , Receptor fas/fisiología
19.
Nihon Ishinkin Gakkai Zasshi ; 40(3): 183-8, 1999.
Artículo en Japonés | MEDLINE | ID: mdl-10423514

RESUMEN

A sixty-four-year-old male patient was admitted on 13 April 1995 with diagnosis of old pulmonary tuberculosis and pulmonary aspergilloma. He developed a tarry stool and frequent loose motion in early November 1995. Histopathological findings of endoscopic biopsy from the duodenum and colon were suggestive of secondary amyloidosis. In spite of antibiotic and steroid pulse, he developed shock, and massive infiltration shadow appeared in chest X-ray. The patient died on 29 December 1995. The postmortem examination in the specimens of the lung, heart, kidney, liver, and spleen revealed hyphae of Aspergillus sp. and in the specimens of the lung, kidney, spleen, esophagus, adrenal gland, and thyroid revealed amyloid. He was finally diagnosed as invasive aspergillosis with secondary amyloidosis.


Asunto(s)
Amiloidosis/etiología , Aspergilosis/complicaciones , Enfermedades Pulmonares Fúngicas/complicaciones , Infecciones Oportunistas/complicaciones , Humanos , Huésped Inmunocomprometido , Masculino , Persona de Mediana Edad , Tuberculosis Pulmonar/complicaciones
20.
Clin Exp Immunol ; 115(3): 485-90, 1999 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-10193422

RESUMEN

Cryptococcus neoformans causes infection in individuals with defective T cell function, such as AIDS, as well as without underlying disease. It has been suggested that humoral as well as cellular immunity might play an important role in the immune response to C. neoformans infection. We have recently shown, using immunoblotting, that the 70-kD hsp family of C. neoformans was the major target molecule of the humoral response in murine pulmonary cryptococcosis. In this study we also used immunoblotting to define the antibody responses in the sera of 24 patients with pulmonary cryptococcosis: 21 proven and three suspected diagnoses. Anti-C. neoformans hsp70 antibody was detected in 16 of 24 (66.7%) patients with pulmonary cryptococcosis. Fourteen of 17 (82.3%) patients with high antigen titres (> or = 1:8) and two of seven (28.6%) patients with low titres (< or = 1:4) had detectable levels of anti-hsp70 antibody. Sera from patients positive for anti-hsp70 antibody showed high titres in the Eiken latex agglutination test for the detection of serum cryptococcal antigen. Our results indicate that the 70-kD hsp family from C. neoformans appears to be a major target molecule of the humoral response, not only in murine pulmonary cryptococcosis, but also in human patients with pulmonary cryptococcosis.


Asunto(s)
Anticuerpos Antifúngicos/sangre , Criptococosis/inmunología , Cryptococcus neoformans/inmunología , Proteínas Fúngicas/inmunología , Proteínas HSP70 de Choque Térmico/inmunología , Enfermedades Pulmonares Fúngicas/inmunología , Adulto , Anciano , Animales , Antígenos Fúngicos/sangre , Estudios de Casos y Controles , Criptococosis/microbiología , Femenino , Proteínas Fúngicas/sangre , Proteínas HSP70 de Choque Térmico/sangre , Humanos , Enfermedades Pulmonares Fúngicas/microbiología , Masculino , Ratones , Persona de Mediana Edad
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...